



## **Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference**

**December 4, 2023 9:00 PM EST**

CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4<sup>th</sup> Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023, at 9:30 a.m. ET.

A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at [www.omegatherapeutics.com](http://www.omegatherapeutics.com). An archived replay will be available on the same website for approximately 90 days.

### **About Omega Therapeutics**

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega's approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visit [omegatherapeutics.com](http://omegatherapeutics.com), or follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

Investor Contact: Eva Stroynowski 617.949.4370 [estroynowski@omegatx.com](mailto:estroynowski@omegatx.com)